These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1392 related articles for article (PubMed ID: 8727307)

  • 1. Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis.
    De Wit PE; Van Muijen GN; De Waal RM; Ruiter DJ
    Curr Opin Oncol; 1996 Mar; 8(2):143-51. PubMed ID: 8727307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of metastasizing and nonmetastasizing human melanoma cells.
    van Muijen GN; Danen EH; de Vries TJ; Quax PH; Verheijen JH; Ruiter DJ
    Recent Results Cancer Res; 1995; 139():105-22. PubMed ID: 7597284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma.
    Danen EH; Van Muijen GN; Ruiter DJ
    Cancer Surv; 1995; 24():43-65. PubMed ID: 7553662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.
    Fröhlich E
    Cell Mol Life Sci; 2010 Dec; 67(23):3947-60. PubMed ID: 20686912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
    de Vries TJ; van Muijen GN; Ruiter DJ
    Melanoma Res; 1996 Apr; 6(2):79-88. PubMed ID: 8791264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44 and variants in melanocytic skin neoplasms.
    Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
    J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrins and other adhesion molecules involved in melanocytic tumor progression.
    Edward M
    Curr Opin Oncol; 1995 Mar; 7(2):185-91. PubMed ID: 7756384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
    Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
    Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of melanocytic tumour progression.
    Ruiter DJ; van Muijen GN
    J Pathol; 1998 Dec; 186(4):340-2. PubMed ID: 10209480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous melanoma: pathology, relevant prognostic indicators and progression.
    Slominski A; Ross J; Mihm MC
    Br Med Bull; 1995 Jul; 51(3):548-69. PubMed ID: 7552081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
    Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.
    Poukka M; Bykachev A; Siiskonen H; Tyynelä-Korhonen K; Auvinen P; Pasonen-Seppänen S; Sironen R
    BMC Cancer; 2016 May; 16():313. PubMed ID: 27184066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular markers of circulating melanoma cells.
    Medic S; Pearce RL; Heenan PJ; Ziman M
    Pigment Cell Res; 2007 Apr; 20(2):80-91. PubMed ID: 17371435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal reaction in cutaneous melanoma.
    Labrousse AL; Ntayi C; Hornebeck W; Bernard P
    Crit Rev Oncol Hematol; 2004 Mar; 49(3):269-75. PubMed ID: 15036266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathologic diagnosis, staging and prognostic factors of melanoma and management of primary disease.
    Ruiter DJ
    Curr Opin Oncol; 1992 Apr; 4(2):357-67. PubMed ID: 1591309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes.
    Knutson JR; Iida J; Fields GB; McCarthy JB
    Mol Biol Cell; 1996 Mar; 7(3):383-96. PubMed ID: 8868467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of diagnostic and prognostic markers in cutaneous malignant melanoma.
    Reed JA; Albino AP
    Dermatol Clin; 1999 Jul; 17(3):631-43. PubMed ID: 10410863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor biomarkers in melanoma.
    Ugurel S; Utikal J; Becker JC
    Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
    Dundr P; Simon K; Němejcová K; Bártů M; Tichá I; Michálková R; Jakša R; Věcková Z; Kodet O
    Melanoma Res; 2019 Apr; 29(2):157-162. PubMed ID: 30422880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.